Nakajima I, Okuno K, Ohnishi H, Shilayama Y, Nakamura T, Hirohata T, Yasutomi M
First Department of Surgery, Kinki University, School of Medicine, Osaka, Japan.
Nihon Geka Gakkai Zasshi. 1990 Oct;91(10):1548-53.
We have so far investigated the method to induce LAK cells efficiently within the body by direct intrasplenic injection of Interleukin 2 (IL-2) in tumor bearing mice. In this study we used IL-2 in combination with rTNF in an attempt to induce effectively much stronger LAK cells and found that the combined use resulted in not only enhancement but also significant prolongation of LAK activity. Furthermore, the combined use also yielded in vivo effect, that is prolongation of the mouse survival. This study suggests that the combined use of IL-2 and TNF may promise more effective induction of LAK cells in the organism with much smaller doses of IL-2. The combined use may be helpful to improve the treatment regimen by intra arterial injection of IL-2 that we have so far conducted, possibly leading to a higher response rate in clinical setting.
迄今为止，我们已经研究了通过向荷瘤小鼠脾脏内直接注射白细胞介素2（IL-2）在体内有效诱导LAK细胞的方法。在本研究中，我们将IL-2与rTNF联合使用，试图有效诱导更强的LAK细胞，结果发现联合使用不仅增强了LAK活性，还显著延长了其活性。此外，联合使用还产生了体内效应，即延长了小鼠生存期。本研究表明，IL-2和TNF联合使用可能有望以更小剂量的IL-2在机体中更有效地诱导LAK细胞。这种联合使用可能有助于改进我们迄今为止进行的经动脉注射IL-2的治疗方案，可能在临床环境中带来更高的缓解率。
